Health benefits of combined oral contraceptives - a narrative review
CONCLUSIONS: The use of combined oral contraceptives is accompanied with a range of health benefits, to be balanced against its side-effects and risks. Several health benefits of COCs are a reason for non-contraceptive COC prescription.PMID:38426312 | DOI:10.1080/13625187.2024.2317295 (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - March 1, 2024 Category: Reproduction Medicine Authors: Herjan J T Coelingh Bennink Femke A M van Gennip Mireille G F Gerrits Jan F M Egberts Kristina Gemzell-Danielsson Helena Kopp-Kallner Source Type: research
Health benefits of combined oral contraceptives - a narrative review
CONCLUSIONS: The use of combined oral contraceptives is accompanied with a range of health benefits, to be balanced against its side-effects and risks. Several health benefits of COCs are a reason for non-contraceptive COC prescription.PMID:38426312 | DOI:10.1080/13625187.2024.2317295 (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - March 1, 2024 Category: Reproduction Medicine Authors: Herjan J T Coelingh Bennink Femke A M van Gennip Mireille G F Gerrits Jan F M Egberts Kristina Gemzell-Danielsson Helena Kopp-Kallner Source Type: research
RNA therapeutics for metabolic disorders
Prog Mol Biol Transl Sci. 2024;203:181-196. doi: 10.1016/bs.pmbts.2023.12.014. Epub 2024 Jan 25.ABSTRACTThe prevalence of metabolic disorders is increasing exponentially and has recently reached epidemic levels. Over the decades, a large number of therapeutic options have been proposed to manage these diseases but still show several limitations. In this circumstance, RNA therapeutics have rapidly emerged as a new hope for patients with metabolic diseases. 57 years have elapsed from the discovery of mRNA, a large number of RNA-based drug candidates have been evaluated for their therapeutic effectiveness and clinical safety ...
Source: Mol Biol Cell - February 15, 2024 Category: Molecular Biology Authors: Thuy-Duong Vu Sheng-Che Lin Chia-Ching Wu Dinh-Toi Chu Source Type: research
RNA therapeutics for metabolic disorders
Prog Mol Biol Transl Sci. 2024;203:181-196. doi: 10.1016/bs.pmbts.2023.12.014. Epub 2024 Jan 25.ABSTRACTThe prevalence of metabolic disorders is increasing exponentially and has recently reached epidemic levels. Over the decades, a large number of therapeutic options have been proposed to manage these diseases but still show several limitations. In this circumstance, RNA therapeutics have rapidly emerged as a new hope for patients with metabolic diseases. 57 years have elapsed from the discovery of mRNA, a large number of RNA-based drug candidates have been evaluated for their therapeutic effectiveness and clinical safety ...
Source: Mol Biol Cell - February 15, 2024 Category: Molecular Biology Authors: Thuy-Duong Vu Sheng-Che Lin Chia-Ching Wu Dinh-Toi Chu Source Type: research
A case report of acute intermittent porphyria leading to severe disability
We present a case with multiple typical clinical manifestations of AIP in the hope of aiding clinicians in fully recognizing acute intermittent porphyria. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - January 11, 2024 Category: Neurology Source Type: research
Obstacles to Early Diagnosis of Acute Hepatic Porphyria: Current Perspectives on Improving Early Diagnosis and Clinical Management
(Source: Clinical and Experimental Gastroenterology)
Source: Clinical and Experimental Gastroenterology - January 5, 2024 Category: Gastroenterology Tags: Clinical and Experimental Gastroenterology Source Type: research
Porphyria cutanea tarda in a human immunodeficiency virus-positive patient
Med Clin (Barc). 2023 Dec 26:S0025-7753(23)00710-8. doi: 10.1016/j.medcli.2023.10.026. Online ahead of print.NO ABSTRACTPMID:38151366 | DOI:10.1016/j.medcli.2023.10.026 (Source: Medicina Clinica)
Source: Medicina Clinica - December 27, 2023 Category: General Medicine Authors: Andr és Grau-Echevarría Carolina Labrandero-Hoyos Rodrigo Pe ñuelas-Leal Daniel Blaya-Imbern ón Malena Finello Gemma Mar ía Pérez-Pastor Pablo Hern ández-Bel Amparo P érez-Ferriols Source Type: research
Functional and structural analysis of a novel splice site HMBS variant in a Chinese AIP patient
Conclusion: The study identified and proved the pathogenicity of a novel splice site HMBS variant for the first time. Our results elucidated the pathological mechanism by which this mutation causes AIP through reducing HMBS expression and activity. These findings provide theoretical guidance for the diagnosis, treatment and genetic counseling of AIP patients. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - December 19, 2023 Category: Genetics & Stem Cells Source Type: research
Clinical feature and genetic analysis of HMBS gene in Chinese patients with acute intermittent porphyria: a systematic review
Conclusion: The most common presenting symptom in Chinese AIP patients was abdominal pain, followed by central nervous system symptoms. The HMBS gene analysis in Chinese AIP patients revealed that the heterogeneity is strong and the most common variant was missense mutation, with c.517C>T being the most common variant. The genotype-phenotype association helps guide clinical diagnosis and treatment. However, the treatment for AIP in China is limited and monolithic, and more attention needs to be paid to the treatment. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - December 11, 2023 Category: Genetics & Stem Cells Source Type: research
Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study
Acute hepatic porphyria (AHP) is a family of rare genetic diseases, including acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and delta-aminolevulinic acid dehydratase-deficient p... (Source: Orphanet Journal of Rare Diseases)
Source: Orphanet Journal of Rare Diseases - December 8, 2023 Category: Internal Medicine Authors: Yutaka Horie, Yuka Yasuoka and Tomohide Adachi Tags: Research Source Type: research
Premenstrual abdominal pain and posterior reversible encephalopathy syndrome in a woman with acute intermittent porphyria: A case report
Asian J Surg. 2023 Dec 6:S1015-9584(23)01946-2. doi: 10.1016/j.asjsur.2023.11.150. Online ahead of print.NO ABSTRACTPMID:38061950 | DOI:10.1016/j.asjsur.2023.11.150 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - December 7, 2023 Category: Surgery Authors: Haixia Wang Yuan Xie Source Type: research
Premenstrual abdominal pain and posterior reversible encephalopathy syndrome in a woman with acute intermittent porphyria: A case report
Asian J Surg. 2023 Dec 6:S1015-9584(23)01946-2. doi: 10.1016/j.asjsur.2023.11.150. Online ahead of print.NO ABSTRACTPMID:38061950 | DOI:10.1016/j.asjsur.2023.11.150 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - December 7, 2023 Category: Surgery Authors: Haixia Wang Yuan Xie Source Type: research
A high urinary urobilinogen/serum total bilirubin ratio indicates acute hepatic porphyria in patients with abdominal pain
Sci Rep. 2023 Dec 4;13(1):21330. doi: 10.1038/s41598-023-48824-9.ABSTRACTAcute hepatic porphyria (AHP) has always been a diagnostic dilemma for physicians due to its variable symptoms. Correct diagnosis mainly depends on the detection of an elevated urinary porphobilinogen (PBG), which is not a routine test and highly relies on the physician's awareness of AHP. In the present study, we identified a more convenient indicator during routine examinations to improve the diagnosis of AHP. We found that AHP patients showed a significant higher "FALSE" urinary urobilinogen level caused by urinary PBG during the urinalysis when de...
Source: Pain Physician - December 3, 2023 Category: Anesthesiology Authors: Chengyuan Song Yuan Liu Source Type: research
A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort
CONCLUSIONS: Long-term efficacy and safety results in the Taiwan cohort are consistent with those in the global cohort.PMID:38044204 | DOI:10.1016/j.jfma.2023.10.016 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - December 3, 2023 Category: General Medicine Authors: Ming-Jen Lee Hung-Chou Kuo Lin-Na Chou Marianne T Sweetser Jiaan-Der Wang Source Type: research
